New York University School of Medicine New York, NY.
Medical therapy for the treatment of benign prostatic hyperplasia (BPH) became an accepted standard of care in the 1990s following the reports of randomized, double-blind, placebo-controlled studies showing that finasteride, a 5-α reductase inhibitor, and terazosin, an α-blocker, significantly improved lower urinary tract symptoms and increased peak urinary flow rates in men with BPH. This article reviews novel approaches to the pharmacological treatment of BPH.
Written by:
Lepor H. Are you the author?
Reference: Rev Urol. 2011;13(1):20-33.
PubMed Abstract
PMID: 21826125
UroToday.com BPH and Male LUTS Section
